TPST

Tempest Therapeutics Inc. (TPST) | Rumor.io

Tempest Therapeutics

TPST

Attention (50-day avg)0%

Attention rank (50-day avg)#1,175

Bullish sentiment (50-day avg)79%

Price to earnings ratio-0.13

Market capitalization13.8M

Earnings per share-3.68

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-26.3M

Social

What share of all stock conversation is about TPST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% -0.01	0% +0	0% -0.01

Sep 22

Tempest Therapeutics, Inc. ($TPST) has seen significant growth, with some investors expecting a short squeeze due to high borrow rates and limited shares available.
The company's tendency to release news before or after market hours may be contributing to its volatility, with some investors speculating that news is forthcoming.
$TPST has been upgraded by a research lead, citing its momentum and strong volume, but no trade recommendation is made.

Generated by AI

Sentiment

Of the messages about TPST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	77.78% -4.3	81.02% +11.21	77.31% -13.04
Bearish	0%	22.22% +4.3	18.98% -11.21	22.69% +13.04

Bullish· Sep 16

Insider buying has been strong, with $1.0 million in purchases from company insiders, and no insider selling.
The company's recent deal has been well-received, with a 35% increase in stock price after-hours.
The stock is setting up for a potential short squeeze, with a possible target of $57-$75 per share in a potential buyout.

Bearish· Sep 16

The company's share price is highly volatile, with some users expressing frustration with the asset's inability to break above $1.30.
There are concerns about the company's financials, with one user pointing out the issuance of millions of warrants at a low price as a potential form of dilution.
The share price has been unable to hold new levels, with users predicting a downward spiral if buyers stop trying to purchase at the ask price.

Generated by AI

Topics

Of the messages about TPST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	37.4%	67.76%
Technical Analysis	0%	0%	61.83%	19.98%
Controversies	0%	0%	0%	1.69%
Macro	0%	0%	0.76%	5.87%
Analysts	0%	0%	0%	3.75%
Earnings	0%	0%	0%	0.95%

Analysts· Oct 12

Analyst HC Wainwright raised the price target for Tempest Therapeutics (TPST) to $47 from $35, maintaining a Buy rating.
Analyst Joseph Pantginis of HC Wainwright believes Tempest Therapeutics is strongly positioned for business development, citing the company's global development and commercialization rights for its TPST-1120 drug.
The majority of analysts (86%) recommend buying TPST, indicating a high level of confidence in the stock.

Announcements· Apr 10

Tempest Therapeutics, Inc. (TPST) announced a partnership for TPST-2003 ahead of a planned U.S. registrational study in 2026.
The company completed a strategic CAR-T acquisition, which is seen as a major catalyst for the stock's surge.
A new CEO appointment is also cited as a positive factor, along with positive interim data from the company.

Technical Analysis· Oct 16

$TPST is forming a bullish wedge on the 5-minute chart, with an inverted H&S pattern also developing.
The stock has shown a double bottom on the daily chart, with yesterday's close becoming new support and consolidating.
Technical indicators are bullish, with a 9-21 day email cross over and a recent retest of the pre-market trend line, suggesting a potential breakout.

Generated by AI

Community

Of the messages about TPST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	44.19%	43.96%	81.48%
Newcomers	0%	55.81%	56.04%	18.52%

Regulars· Sep 17

Tempest Therapeutics' licensing deal with Senlang includes an exclusive option to develop and commercialize Senlang's in-vivo CAR-T technology worldwide, with an option exercise fee of approximately $447,000 and escalating annual maintenance fees.
The company's shares were down 25.4% due to sharp profit-taking, with some participants calling for a tender offer and questioning management's intentions.
Tempest Therapeutics has secured an $800M deal for its TPST-4003, which has received FDA approval and is on a fast track to market, with a marketing application flagged by the EMA.

Newcomers· Sep 17

Newcomers are excited about Tempest Therapeutics' (TPST) rapid price increase, with some mentioning a 133% rise in a short period.
The company's recent exclusive option agreement to license Senlang's CDZ-targeted lentiviral vector platform and portfolio of in vivo CAR-T product candidates is seen as a major development.
There is a need for increased trading volume in TPST, with some users expressing optimism about the stock's potential for further growth.

Generated by AI

News

Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket

14d agoBenzinga

Tempest Therapeutics Shares Surge 66.53% After Hours on CAR-T Deal - Tempest Therapeutics (NASDAQ:TPST)

14d agoBenzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session

14d agoBenzinga

Also Discussed

Investors talking about TPST also mention

#	Name	Attention
1	SECO - Secoo Holding Limited	——
2	Femasys Inc.FEMY	0%+0
3	Naya Biosciences Inc.INVO	0%0
4	BNOX - Bionomics Limited	——
5	FRBN - Forbion European Acquisition Corp.	——
6	ParaZero Technologies Ltd.PRZO	0%+0
7	Avalo Therapeutics, Inc.AVTX	0%0
8	Cardio Diagnostics Holdings, Inc.CDIO	0%0
9	Versus Systems Inc.VS	0%0
10	LMDX - LumiraDx Limited	——

Tempest Therapeutics Inc.

Healthcare
Biotechnology

Tempest Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cancer therapies through targeted and immune-mediated mechanisms. The company’s current pipeline centers on small molecule and cell therapy programs designed to address multiple oncology indications, including solid tumors and hematologic cancers. Its portfolio includes advanced investigational candidates that aim to modulate tumor biology, enhance anti-tumor immune responses, and broaden the reach of next-generation cell therapy approaches. Tempest Therapeutics also works with partners on certain clinical programs, reflecting a business model centered on drug development, clinical research, and translational oncology. Based in Brisbane, California, Tempest Therapeutics Inc. operates within the biopharmaceutical sector as a research-driven company advancing experimental treatments toward clinical evaluation.

Website

Location

2000 Sierra Point Parkway

Brisbane, CA, 94005

United States

Social

What share of all stock conversation is about TPST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% -0.01	0% +0	0% -0.01

Sep 22

Tempest Therapeutics, Inc. ($TPST) has seen significant growth, with some investors expecting a short squeeze due to high borrow rates and limited shares available.
The company's tendency to release news before or after market hours may be contributing to its volatility, with some investors speculating that news is forthcoming.
$TPST has been upgraded by a research lead, citing its momentum and strong volume, but no trade recommendation is made.

Generated by AI

Sentiment

Of the messages about TPST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	77.78% -4.3	81.02% +11.21	77.31% -13.04
Bearish	0%	22.22% +4.3	18.98% -11.21	22.69% +13.04

Bullish· Sep 16

Insider buying has been strong, with $1.0 million in purchases from company insiders, and no insider selling.
The company's recent deal has been well-received, with a 35% increase in stock price after-hours.
The stock is setting up for a potential short squeeze, with a possible target of $57-$75 per share in a potential buyout.

Bearish· Sep 16

The company's share price is highly volatile, with some users expressing frustration with the asset's inability to break above $1.30.
There are concerns about the company's financials, with one user pointing out the issuance of millions of warrants at a low price as a potential form of dilution.
The share price has been unable to hold new levels, with users predicting a downward spiral if buyers stop trying to purchase at the ask price.

Generated by AI

Topics

Of the messages about TPST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	37.4%	67.76%
Technical Analysis	0%	0%	61.83%	19.98%
Controversies	0%	0%	0%	1.69%
Macro	0%	0%	0.76%	5.87%
Analysts	0%	0%	0%	3.75%
Earnings	0%	0%	0%	0.95%

Analysts· Oct 12

Analyst HC Wainwright raised the price target for Tempest Therapeutics (TPST) to $47 from $35, maintaining a Buy rating.
Analyst Joseph Pantginis of HC Wainwright believes Tempest Therapeutics is strongly positioned for business development, citing the company's global development and commercialization rights for its TPST-1120 drug.
The majority of analysts (86%) recommend buying TPST, indicating a high level of confidence in the stock.

Announcements· Apr 10

Tempest Therapeutics, Inc. (TPST) announced a partnership for TPST-2003 ahead of a planned U.S. registrational study in 2026.
The company completed a strategic CAR-T acquisition, which is seen as a major catalyst for the stock's surge.
A new CEO appointment is also cited as a positive factor, along with positive interim data from the company.

Technical Analysis· Oct 16

$TPST is forming a bullish wedge on the 5-minute chart, with an inverted H&S pattern also developing.
The stock has shown a double bottom on the daily chart, with yesterday's close becoming new support and consolidating.
Technical indicators are bullish, with a 9-21 day email cross over and a recent retest of the pre-market trend line, suggesting a potential breakout.

Generated by AI

Community

Of the messages about TPST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	44.19%	43.96%	81.48%
Newcomers	0%	55.81%	56.04%	18.52%

Regulars· Sep 17

Tempest Therapeutics' licensing deal with Senlang includes an exclusive option to develop and commercialize Senlang's in-vivo CAR-T technology worldwide, with an option exercise fee of approximately $447,000 and escalating annual maintenance fees.
The company's shares were down 25.4% due to sharp profit-taking, with some participants calling for a tender offer and questioning management's intentions.
Tempest Therapeutics has secured an $800M deal for its TPST-4003, which has received FDA approval and is on a fast track to market, with a marketing application flagged by the EMA.

Newcomers· Sep 17

Newcomers are excited about Tempest Therapeutics' (TPST) rapid price increase, with some mentioning a 133% rise in a short period.
The company's recent exclusive option agreement to license Senlang's CDZ-targeted lentiviral vector platform and portfolio of in vivo CAR-T product candidates is seen as a major development.
There is a need for increased trading volume in TPST, with some users expressing optimism about the stock's potential for further growth.

Generated by AI

Tempest Therapeutics

Social

Sep 22

Bullish· Sep 16

Bearish· Sep 16

Analysts· Oct 12

Announcements· Apr 10

Technical Analysis· Oct 16

Regulars· Sep 17

Newcomers· Sep 17

Tempest Therapeutics appoints Nancy Freda-Smith to board

Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action?

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket

Tempest Therapeutics Shares Surge 66.53% After Hours on CAR-T Deal - Tempest Therapeutics (NASDAQ:TPST)

12 Health Care Stocks Moving In Tuesday's After-Market Session

Also Discussed

Tempest Therapeutics Inc.

Company Information

Location

Tempest Therapeutics appoints Nancy Freda-Smith to board

Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action?

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket

Tempest Therapeutics Shares Surge 66.53% After Hours on CAR-T Deal - Tempest Therapeutics (NASDAQ:TPST)

12 Health Care Stocks Moving In Tuesday's After-Market Session

Also Discussed

Social

Sep 22

Bullish· Sep 16

Bearish· Sep 16

Analysts· Oct 12

Announcements· Apr 10

Technical Analysis· Oct 16

Regulars· Sep 17

Newcomers· Sep 17